ITK
Tyrosine-protein kinase ITK/TSK
As of the edition of 20 October 2026, ITK (tyrosine-protein kinase ITK/TSK, UniProt Q08881) has 4 drugs tested at it and 6 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q08881
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 37
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Hormones; Lungs and airways; Digestive system; Immune system
- Registered trials of its drugs
- 313
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pazopanib | Marketed | Phase 4 | none listed |
| Ritlecitinib | Marketed | Phase 3 | Ends 2041 |
| Soquelitinib | Active | Phase 3 | none listed |
| JTE-051 | Stopped | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Pfizer | Route B |
| Akros Pharma | Route A |
The other 3 companies at ITK
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at ITK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.